openPR Logo
Press release

Theranostics Market Application Analysis, Regional Outlook, Competitive Strategies and Forecast 2026

10-23-2019 08:02 AM CET | Health & Medicine

Press release from: Coherent Market Insight

Theranostics Market

Theranostics Market

Theranostics involves combination of targeted diagnostic tests with targeted therapy. It is also known as companion diagnostics, integrated medicine, Dx/Rx partnering, and pharmacodiagnostics. Implementation of theranostics into the patient care plan (in case of selected diseases for which diagnostic tests are available along with respective therapy) may turn into personalized therapy, which could further improve medical outcomes.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2043

Theranostics include use of specific diagnostic test, which shows a particular molecular target on a tumor or any other disease causing agent. Any disease pathophysiology involves specific biological pathways, which are targeted with the help of diagnostic tests. Diagnostic images of the particular molecule then identifies presence of the specific mutation or receptors (in case of cancer), which can be targeted with the help of therapeutic agents. This approach avoids trial and error treatment and could be used to offer patient specific treatment at the right time. Accurate dose calibration and precisely targeted approach could highly be useful in management of chronic diseases such as cancer.

For instance, neuro endocrine tumors can be diagnosed to assess extent of disease via PET-CT (Positron Emission Tomography – Computer Tomography) using Ga-68 DOTATOC (a radioactive positron emitter). Ga-68 targets somatostatin receptor (SSTR2) on the tumor cell membrane, and is injected through vein, which travels and binds to the SSTR2 indication the presence of tumor on PET scan. Furthermore, Ga-68 can be replaced by a therapeutic agent to target the tumor.

Global Theranostics Market Drivers:-

Development of novel companion diagnostic tests to be used with available treatment options is expected to boost the global theranostics market growth over the forecast period. Leading manufacturers are engaged in introduction of novel companion diagnostic tests in market. For instance, Illumina, Inc. announced launch of the U.S. Food & Drug Administration (FDA) approved extended RAS panel for identification of patients eligible for treatment of metastatic colorectal cancer with Vectibix (panitumumab) in 2017.

Increasing adoption of companion diagnostic tests by laboratories is further expected to foster global theranostics market growth over the forecast period. BloodCenter of Wisconsin's Diagnostic Laboratories started offering Abbott RealTime IDH1 assay for patients with acute myeloid leukemia (AML) in July 2018. Moreover, Cancer Genetics, Inc. started offering FDA approved companion diagnostic Thermo Fisher Scientific's Oncomine Dx Target - the first Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) test in 2017. Laboratory Corporation of America Holdings launched OmniSeq Advance in partnership with OmniSeq for tumor cancers in June 2018.

Partnerships and collaborations by leading manufacturers to develop innovative companion diagnostics is expected to foster global theranostics market growth over the forecast period. For instance, Foundation Medicine, Inc. and Pfizer, Inc. entered into a partnership for development, regulatory support, and commercialization of companion diagnostics (CDx) in January 2018. Moreover, Qiagen, Inc., and Freenome partnered in June 2018, to accelerate the development and commercialization of Next-Generation Sequencing (NGS) tests to enable precision medicine in cancer treatment.

Pierre Fabre and Roche have been working on development of a robust prototype immunohistochemistry assay as a future companion diagnostic test for W0101 (the drug candidate which they are developing together) and extended this collaboration in May 2018. Abbott Laboratories, Inc. collaborated with Celgene Corporation, and Agios Pharmaceuticals, to develop diagnostic tests on Abbott’s m2000 RealTime system that identifies certain genomic mutations associated with acute myeloid leukemia (AML) in 2016. These factors are expected to support global theranostics market growth over the forecast period.

However, improperly defined regulations for these tests coupled with inadequate reimbursement facilities are expected to hamper growth of the global theranostics market over the forecast period.

Global Theranostics Market Regional Insights:-

North America is expected to witness significant growth in the global theranostics market over the forecast period. Presence of leading manufacturers, collaborations, robust research, and development activities, and increasing adoption of companion diagnostics is expected to support global theranostics market growth over the forecast period. Biocartis Group NV and Amgen, Inc. partnered to develop companion diagnostic test for Amgen's drug Vectibix (panitumumab) in 2017. For instance, Genome Canada launched a national initiative for clinical implementation of precision health in June 2018, which would ultimately impact global theranostics market growth over the forecast period.

Asia Pacific theranostics market is expected to witness significant growth over the forecast period, owing to collaborations in the region by global organizations and increasing awareness regarding companion diagnostics. For instance, Qiagen collaborated with Japan based clinical lab testing company, SRL, Inc. for introduction of new companion diagnostics with new drug approvals in August 2018.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2043

Key players of Global Theranostics Market:-

Key players operating in the global theranostics market include Thermo Fisher Scientific, Inc., Beckman Coulter, Inc., Focus Diagnostics, AmeriPath, Inc., Illumina, Inc., F.Hoffmann LA-Roche Ltd., Qiagen NV, Myriad Genetics, Inc., Agilent Technologies, Abbott Laboratories, Foundation Medicine, Inc., and Oxford Cancer Biomarkers, Ltd.

Global Theranostics Market Taxonomy:-

Global theranostics market is segmented on the basis of therapeutic area, technology, end users, and region

By Therapeutic Area-

Oncology
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Others
Cardiovascular Diseases
Neurological Disorders
Immunological Disorders
Others

By Technology:-

Polymerase Chain Reaction (PCR)
Immunohistochemistry
In Situ Hybridization
Sequencing
Others

By End User:-

Hospitals
Diagnostic Laboratories
Others

By Region:-

North America
Europe
Latin America
Asia Pacific
Middle East
Africa

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Theranostics Market Application Analysis, Regional Outlook, Competitive Strategies and Forecast 2026 here

News-ID: 1855016 • Views:

More Releases from Coherent Market Insight

Cervical Dysplasia Market Size Likely to be valued at US$ 784.8 Million by 2030, Future Trends, Key Insights and Business Strategies for F. Hoffmann La-Roche Ltd., QIAGEN N.V., Becton, Dickinson and Company
Cervical Dysplasia Market Size Likely to be valued at US$ 784.8 Million by 2030, …
Cervical dysplasia, a condition characterized by abnormal cell changes in the cervix, is often linked to human papillomavirus (HPV) infection and smoking. It primarily affects women above the age of 30. However, it's crucial to note that cervical dysplasia is preventable, and regular cervical screening tests play a vital role in the early diagnosis of precancerous stages. This overview focuses on the key factors associated with cervical dysplasia and highlights preventive
High Potency Active Pharmaceutical Ingredients Market Size Likely to be valued at US$ 40.99 Billion by 2030, Booming Growth, Outlook, and Future Prospects | Biomedica Management Corporation, NuvOxPharma LLC
High Potency Active Pharmaceutical Ingredients Market Size Likely to be valued a …
The global High Potency Active Pharmaceutical Ingredients market size is expected to reach USD 40.99 billion by 2030, registering a CAGR of 9.9% from 2023 to 2030, according to a new report by Coherent Market Insight Inc. High potency active pharmaceutical ingredients (HPAPIs) encompass small-molecule compounds, biologics, and antibody-drug conjugates that play a crucial role in modern medicine. With their ability to precisely and selectively target diseased cells, HPAPIs have
Virtual Rehabilitation and Telerehabilitation System Market is a rapidly growing industry Overview 2030 by Top Key Players | Reflexion Health, 270 Vision Ltd., CoRehab srl
Virtual Rehabilitation and Telerehabilitation System Market is a rapidly growing …
The global virtual rehabilitation and telerehabilitation systems market is expected to exhibit a CAGR of 19.2% during the forecast period (2023-2030). Manufacturers are focused on development and launch of innovative rehabilitation devices, which is expected to drive the virtual rehabilitation and telerehabilitation systems market growth. For instance, in August 2019, Ekso Bionics Holdings launched its EksoNR, the next generation of its EksoGT robotic exoskeleton, developed for neurorehabilitation purposes. The device is
Single Cell Analysis Market 2023-2030 | Industry Insights | Future Trends | Booming Growth | 10X Genomics, Abcam, Agilent
Single Cell Analysis Market 2023-2030 | Industry Insights | Future Trends | Boom …
Single cell analysis allows for the study of individual cells within a complex biological system, providing a more detailed and comprehensive understanding of cellular behavior and function. This technology has been instrumental in advancing research in various fields, including cancer biology, immunology, and neuroscience. One of the key drivers of the single cell analysis market is the increasing demand for personalized medicine. As researchers gain a better understanding of individual cell

All 5 Releases


More Releases for Theranostics

01-08-2020 | Health & Medicine
TMR
Theranostics Market Is Booming Worldwide Just Published
Global Theranostics Market: An Overview Theranostics is a new field of medicine which relies on targeted therapies to conduct specific targeted tests. These tests are mainly used for various forms of cancers. The key concern in the therapeutics involve patient centric care with the help of more personalised and precise approach. The technique relies on the use of diagnostic and therapeutic applications to form a single agent. The system is known
Theranostics Market Positioning and Growing Market Share Worldwide
Coherent Market Insights Market Reports offers 2019 Depth Insights report on Global Theranostics market that evaluates industry growth trends, through historical data and estimates future prospects based on comprehensive research. The report also identifies the factors driving this market, various restraints and opportunities impacting it along with the adoption trends for the period 2018-2026. The Theranostics market research report displays the latest industry insights with future trends and analysis of the
Theranostics Market Scope and Opportunities Analysis 2016 - 2014
Global Theranostics Market: Overview Theranostics is considered as a fusion of diagnostics and drug therapy. It helps in optimizing safety, effective results, and streamlining of overall drug development. The combination of advanced diagnostic tests and effective medical drugs has been given several names, such as pharmacodiagnostics, integrated medicine, Dx/Rx partnering, and companion diagnostics. Research activities in this field are contributing extensively towards the growth of the market, as this is considered
Growth Prospects of Global Theranostics Market During 2016 – 2024
Theranostics is considered as a fusion of diagnostics and drug therapy. It helps in optimizing safety, effective results, and streamlining of overall drug development. The combination of advanced diagnostic tests and effective medical drugs has been given several names, such as pharmacodiagnostics, integrated medicine, Dx/Rx partnering, and companion diagnostics. Research activities in this field are contributing extensively towards the growth of the market, as this is considered as a highly
Recent Research: Nanomaterials in Theranostics Market Analysis to 2024
Global Nanomaterials in Theranostics Market: Overview The application of theranostics in nanomedicine is a fast emerging paradigm, which involves the use of nanoparticles or nanoscale materials for a variety of diagnostic, imaging, and therapeutic applications. Recent research efforts have been increasingly focused on designing functional nanomaterials for non-invasive imaging of diseases, including bioimaging and biosensing, advanced biomarkers, and targeted delivery of therapeutic drugs. Efforts are also underway for developing highly
Theranostics Market: Opportunities and Forecasts, 2016 - 2024
Global Theranostics Market: Overview Theranostics is considered as a fusion of diagnostics and drug therapy. It helps in optimizing safety, effective results, and streamlining of overall drug development. The combination of advanced diagnostic tests and effective medical drugs has been given several names, such as pharmacodiagnostics, integrated medicine, Dx/Rx partnering, and companion diagnostics. Research activities in this field are contributing extensively towards the growth of the market, as this is considered